# Allarity Therapeutics, Inc.: overview

ALLR · Nasdaq · CIK 1860657 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/allr.md) · [Financials](/companies/allr/financials.md) · [Filings](/companies/allr/filings.md) · [Insiders](/companies/allr/insiders.md)

Latest reported revenue: [$0](/filings/0001437749-26-027830.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001437749-26-027830).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | [0.0](/filings/0001437749-26-017371.md) | [0.0](/filings/0001437749-26-027830.md) | not reported | not reported | [25.0](/filings/0001437749-26-017371.md) | [0.0](/filings/0001437749-26-027830.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(10752.0%)](/filings/0001437749-26-017371.md) | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(11000.0%)](/filings/0001437749-26-027830.md) | not reported |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $k | not reported | not reported | [(2,686)](/filings/0001437749-26-017371.md) | [(5,481) d](/filings/0001437749-26-027830.md) | not reported | not reported | [(4,557)](/filings/0001437749-26-017371.md) | [(2,564) d](/filings/0001437749-26-027830.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [0.0](/filings/0001437749-26-010310.md) | [0.3](/filings/0001437749-26-010310.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | [(3939.1%)](/filings/0001437749-26-010310.md) |
| Net margin | % | not reported | not reported | not reported | not reported | [(3509.7%)](/filings/0001437749-26-010310.md) |
| Diluted EPS | $ per share | [(4.19)](/filings/0001213900-23-019295.md) | [(3093.42)](/filings/0001213900-24-020864.md) | [(10.26)](/filings/0001213900-24-020864.md) | not reported | not reported |
| Free cash flow | $m | not reported | [(16.8)](/filings/0001213900-24-020864.md) | [(12.7)](/filings/0001437749-25-010198.md) | [(17.7)](/filings/0001437749-26-010310.md) | [(14.8)](/filings/0001437749-26-010310.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/allr/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $427.6k | 331,509 |  | Added +103,425 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $221.6k | 171,795 |  | Unchanged |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $199.8k | 154,867 |  | Reduced −35,526 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $177.5k | 137,600 |  | Unchanged |
| [Militia Capital Management LLC](/funds/2130487.md) | 2026-06-30 | $127.7k | 98,978 |  | New +98,978 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $118.4k | 91,748 |  | New +91,748 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $96.6k | 74,913 |  | Unchanged |
| [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $47.1k | 36,534 |  | Reduced −11,569 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $46.5k | 36,021 |  | New +36,021 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $35.5k | 27,492 |  | Unchanged |

## Recent filings

[All 402 filings](/companies/allr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-30 | 16:05 ET | [8-K](/filings/0001213900-26-114380.md) | 1.02 Termination of a material agreement | 0001213900-26-114380 |
| 2026-10-01 | 08:00 ET | [8-K](/filings/0001213900-26-105457.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-105457 |
| 2026-09-29 | 08:00 ET | [8-K](/filings/0001213900-26-104317.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-104317 |
| 2026-09-16 | 08:00 ET | [8-K](/filings/0001213900-26-100350.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-100350 |
| 2026-09-14 | 12:14 ET | [8-K](/filings/0001213900-26-099576.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-099576 |
| 2026-08-14 | 16:35 ET | [8-K](/filings/0001213900-26-090183.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-090183 |
| 2026-08-14 | 08:02 ET | [10-Q](/filings/0001437749-26-027830.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027830 |
| 2026-07-01 | 08:05 ET | [8-K](/filings/0001213900-26-073998.md) | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-073998 |
| 2026-06-22 | 08:10 ET | [8-K](/filings/0001213900-26-070382.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-070382 |
| 2026-06-02 | 17:10 ET | [8-K](/filings/0001213900-26-064278.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-064278 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-010310.md), filed Mar 30, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/0efdc729-6140-47b0-87aa-ad643718c2f0)

## About the filer

- CIK: 1860657
- Tickers: ALLR
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:18 ET. No prices; not investment advice.